News

Patrick Tan, MD, PhD, Genome Institute of Singapore

Videos

New Strategies for Molecular Classification in Gastric Cancer

08/22/2023

Featuring Patrick Tan, MD, PhD

Featuring Patrick Tan, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on...

08/22/2023

Oncology

Antonella Cammarota, MD, Humanitas University

Videos

Impact of Prior Chemotherapy Administration on Intratumor Heterogeneity of CLDN18.2-Positive Gastroesophageal Cancers

08/21/2023

Featuring Antonella Cammarota, MD

Featuring Antonella Cammarota, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.

At the 2023 World Congress on...

08/21/2023

Oncology

Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori

Videos

Relationship Between Clinicopathological Features and Immunotherapy Benefit Among Patients With dMMR/MSI-High Metastatic or Unresectable Gastric Cancer

08/17/2023

Featuring Giovanni Randon, MD

At the 2023 World Congress on Gastrointestinal Cancers, Giovanni Randon, MD, presented results from a study relating clinicopathological features and immunotherapy benefit among patients with dMMR/MSI-high metastatic or unresectable gastric...

At the 2023 World Congress on...

08/17/2023

Oncology

News

Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer

08/10/2023

Allison Casey

In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.

In a phase 1b/2 study,...

08/10/2023

Oncology

Michael White, MD, MD Anderson Cancer Center

Videos

Mutational Signature Similarities and Differences Between Appendiceal Adenocarcinoma and Colorectal Cancer

07/13/2023

Featuring Michael White, MD

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.

According to a study presented...

07/13/2023

Oncology

Conference Coverage

Nivolumab Plus Chemotherapy Decreases Risk of Deterioration in Health-Related Quality of Life for Patients With Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

06/30/2023

Allison Casey

According to 3-year data, patients with GC/GEJC/EAS treated with nivolumab plus chemotherapy in the CheckMate 649 trial generally maintained health-related quality of life compared to chemotherapy alone.

According to 3-year data,...

06/30/2023

Oncology

Conference Coverage

No Benefit From Adjuvant Nivolumab-Ipilimumab for Patients With Gastroesophageal Adenocarcinoma At High Risk of Relapse

06/29/2023

Allison Casey

According to a phase 2 study, adjuvant nivolumab-ipilimumab did not improve disease-free survival for patients with gastroesophageal adenocarcinoma at high-risk for relapse following resection, compared with chemotherapy.

According to a phase 2 study,...

06/29/2023

Oncology

Conference Coverage

Potential Benefit to Response Rates From Trastuzumab Added to Perioperative Chemotherapy for Patients with HER2-Positive Gastric/Gastroesophageal Junction Cancers

06/29/2023

Allison Casey

A phase 2 trial evaluated the addition of trastuzumab, with or without pertuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal cancer.

A phase 2 trial evaluated the...

06/29/2023

Oncology

Conference Coverage

Sugemalimab Added to Chemotherapy Improves Survival, Response Rates for Patients With Advanced Esophageal Squamous Cell Carcinoma

06/29/2023

Allison Casey

According to results from a phase 3 study, sugemalimab added to chemotherapy improved progression-free survival, overall survival, and objective response rate, for patients with advanced esophageal squamous cell carcinoma.

According to results from a...

06/29/2023

Oncology

Conference Coverage

Addition of Pembrolizumab to Chemotherapy Continues Benefit in Subsequent Therapies for Patients with HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

06/29/2023

Allison Casey

According to data from an ad hoc analysis of the KEYNOTE-859 study, pembrolizumab added to first-line chemotherapy continues to benefit patients with locally advanced or metastatic HER2-negative gastric/gastroesophageal cancer in outcomes of...

According to data from an ad hoc...

06/29/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology